Cost and quality issues in establishing hematopoietic cell transplant program in developing countries
Shahrukh K. Hashmi(Mayo Clinic), Mahmoud Aljurf(King Faisal Specialist Hospital & Research Centre), Amr Nassar(Jouf University), Hildegard Greinix(Medical University of Graz), Walid Rasheed(King Faisal Specialist Hospital & Research Centre), Alok Srivastava(M.J.P. Rohilkhand University), Amir Ali Hamidieh(Stem Cell Technology Research Center), Madan Jagasia(Vanderbilt University Medical Center), Jane F. Apperley(Hammersmith Hospital), Marcelo C. Pasquini(Cleveland Clinic), William Ying Khee Hwang(Singapore General Hospital), Salman Naseem Adil(Cairo University), Tong Wu(Peking University)
Cited by 35
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718